AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02582775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35
Study NCT02582775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor mesenchymal stem cell infusions
Description: Day 60, 100 and 180 (collected during donor BM harvest for graft)
Study NCT02582775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G)
Study NCT03217071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
Study NCT03217071 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiation therapy (SRT)
Description: Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.
Study NCT03217071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (Non-interventional, standard of care)
Description: Standard of care surgery to remove cancer
Study NCT04817163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioral therapy for insomnia (CBT-I)
Description: Each week, the patients first have to read written information on the website (www.insomnet.ca), and then watch a video capsule (duration between 5 and 20 min each). Patients complete their daily sleep diary electronically on the website and the content is interactive. It includes the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
Study NCT04817163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professionally-administered booster face-to-face CBT-I sessions
Description: Patients who obtain an ISI score of 8 and more after completing the web-based CBT-I are stepped up and offered to receive up to three 50-min booster sessions of CBT-I offered individually by a psychologist (if needed). Remitted patients (good sleepers; ISI score lower than 8) will receive no further treatment.
Study NCT01321346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
Study NCT02254525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ibuprofen
Description: Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.
Study NCT02254525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery.
Study NCT01285050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antiretroviral therapy (ART)
Description: Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.
Study NCT01285050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: raltegravir
Description: raltegravir is an HIV medication given 400 mg twice daily by mouth
Study NCT01285050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine and tenofovir disoproxil fumarate
Description: Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
Study NCT01498289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Given IV. Fluorouracil, oxaliplatin, \& leucovorin calcium.
Study NCT01498289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 30 mg/m\^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
Study NCT01498289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 400 mg/m\^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m\^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
Study NCT01498289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 65 mg/m\^2, IV over 90 minutes on Days 1 \& 8 of every 21 day cycle.
Study NCT01498289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 400 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
Study NCT01498289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
Study NCT06135675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092 capsules
Description: TNP-2092 capsules will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.
Study NCT06135675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNP-2092 capsules Placebo
Description: TNP-2092 capsules Placebo will be orally administered 30 min after breakfast and dinner for 14 consecutive days, and last dose will be administered 30 min after breakfast on the morning of D15.
Study NCT01146626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg+ Vitamin D+ Ribavirine
Description: Peg+ Vitamin D+ Ribavirine
Study NCT01146626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg+ Ribavirine
Description: Peg+ Ribavirine
Study NCT04094246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Battlefield Acupuncture
Description: Battlefield Acupuncture (BFA), an auricular acupuncture protocol developed in 2001 by Dr. Niemtzow (Ret. Colonel, USAF), is widely used among civilian and military medical providers to treat pain. Participants in the Experimental Group will receive BFA in addition to standard post-surgical rehabilitation up to four times following their shoulder surgery: 24-hours, 48-hours, 72-hours, and 1-week post-surgery.
Study NCT04094246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-surgical rehabilitation
Description: Participants will receive rehabilitation and will perform a home exercise program in accordance with the standard post-operative shoulder protocol. Participants will be asked to record compliance on an exercise log.
Study NCT02805608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 68Ga-NOTA-AE105
Description: One injection intravenously of 68Ga-NOTA-AE105
Study NCT02805608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 18F-FDG
Description: One injection intravenously of 18F-FDG
Study NCT02805608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and CT
Description: Following of injection of 68Ga-NOTA-AE105 the patients will be PET/CT scanned starting 20 minutes post injection
Study NCT02805608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and MRI
Description: Following injection of 18F-FDG the patients will be PET/MRI scanned starting 60 minutes post injection
Study NCT03358966 — intervention group
Intervention type: OTHER
Intervention: Doubly-labelled water technique
Study NCT03358966 — intervention group
Intervention type: OTHER
Intervention: Resting Energy Expenditure
Description: Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.
Study NCT01779687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: Raltegravir 400 mg BID for 7 days
Study NCT01779687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: Raltegravir 400 mg BID for 7 days
Study NCT01779687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20 mg QD for 7 days
Study NCT01779687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20 mg QD for 7 days
Study NCT04181151 — intervention group
Intervention type: OTHER
Intervention: Electromyographic device
Description: An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
Study NCT00701077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Di-amino-Pyridine
Description: a single 20 mg dosing
Study NCT00701077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03519165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EV1000(FloTrac System 4.0)
Study NCT01519466 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle InsuLinx
Description: FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.
Study NCT01519466 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Freedom Lite
Description: FreeStyle Freedom Lite is a blood glucose meter
Study NCT04744285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette packaging
Description: receive normal packet cigarette
Study NCT04744285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette packaging
Description: receive normal packet cigarette
Study NCT04744285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data capture
Description: Attend video sessions
Study NCT04744285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data capture
Description: Attend video sessions
Study NCT04744285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT04744285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT02688959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Study NCT02688959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT00926211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTAS™ System
Description: Hair harvest using a computer-assisted system
Study NCT00926211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Hair Harvest
Description: Hair harvesting via the manual technique
Study NCT01074619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
Study NCT01074619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
Study NCT01578759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Description: Removal of the fallopian tubes
Study NCT06649578 — intervention group
Intervention type: PROCEDURE
Intervention: Metabolic-bariatric surgery
Description: Our study is conducted in a predominantly high-risk Asian population that will be undergoing metabolic-bariatric surgery. The types of surgery can be divided into Laparoscopic Sleeve Gastrectomy (LSG), Roux-en-Y Gastric Bypass (RYGB) or One-Anastomosis Gastric Bypass (OAGB).
Study NCT04664673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)
Description: motor learning-based, intensive therapy originally developed for hemiplegic children.
Study NCT04664673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: customary or usual treatment given to any adult stroke survivor
Study NCT02426879 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: esophagectomy with three-field lymphnode dissection
Description: robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
Study NCT04746443 — intervention group
Intervention type: OTHER
Intervention: NOT APPLICABLE (NA)
Description: THE INTERVENTION GROUP IS NOT APPLICABLE TO THE CURRENT STUDY DESIGN
Study NCT00939679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Description: Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
Study NCT00939679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass surgery
Description: Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
Study NCT00939679 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low calorie diet (1,000 kcal/day)
Description: Patients will consume a daily diet composed of:~* 4 powder diet portions (Cambridge Diets, UK)~* plain yogurt (100-125g)~* skim milk (1L)~* a limited variety of vegetables~The diet will be consumed by both groups for a 10 week period.
Study NCT00939679 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low calorie diet (1,000 kcal/day)
Description: Patients will consume a daily diet composed of:~* 4 powder diet portions (Cambridge Diets, UK)~* plain yogurt (100-125g)~* skim milk (1L)~* a limited variety of vegetables~The diet will be consumed by both groups for a 10 week period.
Study NCT03000361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motorized Spiral Colonoscopy
Description: For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation
Study NCT02072447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808 PO and [14C]-YH4808 IV
Study NCT03797079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: A high-frequency linear ultrasound probe will be placed superficial to erector spinae muscle (ESM) in a parasagittal plane 3 cm lateral to the midline at the level of fifth thoracic vertebra. Three muscles will be identified superficial to the hyperechoic transverse process shadow: trapezius (uppermost), rhomboids major (middle), and ESM (lowermost). After local infiltration of skin and using in-plane approach, an 18 G Tuohy needle will be inserted, until the tip lay between the rhomboid major muscle and ESM.
Study NCT03797079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEA
Description: Skin will be locally infiltrated at the site of needle insertion, and 18 G Tuohy needle will be introduced until its tip lay in the epidural space of the T5-T6 thoracic intervertebral space.
Study NCT03797079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter insertion
Description: After obtaining loss of resistance, 20 G epidural catheter will be threaded for 5 cm and then fixed on the skin.
Study NCT03797079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours
Study NCT02594124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection
Study NCT03555474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation
Description: Patients were given intermittent TBS to the affected hemisphere and continuous TBS to the unaffected hemisphere for 4 weeks along with physiotherapy.
Study NCT03555474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Patients were given functional electrical stimulation of affected upper extremity for four weeks along with physiotherapy.
Study NCT03555474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Patients received active and passive physiotherapy of the affected extremity for four weeks.
Study NCT03555474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Patients received active and passive physiotherapy of the affected extremity for four weeks.
Study NCT00434473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-001
Description: A-001
Study NCT00434473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03731507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of Range of Motion with Kinect Controller
Description: A ROM measurement method called as KinectROM by us has been developed with Kinect Controller
Study NCT00815672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Progressive walking and resistance exercise treatment
Study NCT00504881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
Study NCT00504881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
Study NCT03498482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)
Description: FORNET aims to reduce trauma-related symptoms and aggressive behavior via narrative exposure of traumatic and violent life events.
Study NCT04372407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib: 200 mg as single dose on Days 1 and 9
Study NCT04372407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14
Study NCT02912325 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Daily administration: 2 tablets FaseMETS a day
Description: Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
Study NCT02148614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
Study NCT02148614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Libramed
Description: Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
Study NCT05146687 — intervention group
Intervention type: OTHER
Intervention: Aflibercept
Description: intravitreal injection
Study NCT05146687 — intervention group
Intervention type: OTHER
Intervention: Ranibizumab
Description: intravitreal injection
Study NCT05146687 — intervention group
Intervention type: OTHER
Intervention: Bevacizumab
Description: intravitreal injection
Study NCT03252171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.
Study NCT02100397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella enterica serovar Paratyphi A (strain NVGH308)
Description: Ingestion of 1-5x10³ to 1-5x10⁵ colony forming units (CFU) of the challenge strain after bicarbonate buffer solution.
Study NCT02127918 — intervention group
Intervention type: DRUG
Intervention: ESES treated with clobazam
Description: The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.